[go: up one dir, main page]

AR025797A1 - Quinazolinonas - Google Patents

Quinazolinonas

Info

Publication number
AR025797A1
AR025797A1 ARP000105076A ARP000105076A AR025797A1 AR 025797 A1 AR025797 A1 AR 025797A1 AR P000105076 A ARP000105076 A AR P000105076A AR P000105076 A ARP000105076 A AR P000105076A AR 025797 A1 AR025797 A1 AR 025797A1
Authority
AR
Argentina
Prior art keywords
quinazolinonas
ibix
quinazolinones
clause
solvates
Prior art date
Application number
ARP000105076A
Other languages
English (en)
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of AR025797A1 publication Critical patent/AR025797A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Quinazolinonas de la formula (1) donde R, R1, R2, R3, R4, Y, Z, n y m tienen los valores que se indican en la cláusula 1, y sus sales o solvatos, que seutilizan como antagonistas de la glicoproteína IbIX.
ARP000105076A 1999-09-28 2000-09-27 Quinazolinonas AR025797A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40795899A 1999-09-28 1999-09-28

Publications (1)

Publication Number Publication Date
AR025797A1 true AR025797A1 (es) 2002-12-11

Family

ID=23614261

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000105076A AR025797A1 (es) 1999-09-28 2000-09-27 Quinazolinonas

Country Status (8)

Country Link
EP (1) EP1216235A1 (es)
KR (1) KR20020047186A (es)
AR (1) AR025797A1 (es)
AU (1) AU7654800A (es)
BR (1) BR0014294A (es)
CA (1) CA2385921A1 (es)
NO (1) NO20021502D0 (es)
WO (1) WO2001023365A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7230000B1 (en) 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
US7671200B2 (en) 1999-10-27 2010-03-02 Cytokinetics, Inc. Quinazolinone KSP inhibitors
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
JP2005529076A (ja) 2002-02-15 2005-09-29 サイトキネティクス・インコーポレーテッド キナゾリノンの合成
AU2003223786A1 (en) 2002-05-09 2003-11-11 Cytokinetics, Inc. Compounds, methods and compositions
WO2003097053A1 (en) 2002-05-09 2003-11-27 Cytokinetics, Inc. Compounds, compositions, and methods
AU2003265242A1 (en) 2002-05-23 2003-12-22 Cytokinetics, Inc. Compounds, compositions, and methods
US7041676B2 (en) 2002-06-14 2006-05-09 Cytokinetics, Inc. Compounds, compositions, and methods
WO2003106435A1 (en) * 2002-06-18 2003-12-24 Sankyo Company, Limited Fused-ring pyrimidin-4(3h)-one derivatives, processes for the preparation and uses thereof
AU2003256805A1 (en) 2002-07-23 2004-02-09 Cytokinetics, Inc. Compounds compositions and methods
US20040152696A1 (en) * 2002-08-01 2004-08-05 Euro-Celtique S.A. 2-substituted bicyclic benzoheterocyclic compounds and their use as sodium channel blockers
US7557115B2 (en) 2002-09-30 2009-07-07 Cytokinetics, Inc. Compounds, compositions, and methods
JP2006512315A (ja) * 2002-11-04 2006-04-13 エヌピーエス ファーマスーティカルズ インコーポレイテッド カルシリティックとしてのキナゾリノン化合物
EP1692112A4 (en) 2003-12-08 2008-09-24 Cytokinetics Inc COMPOUNDS, COMPOSITIONS, AND METHODS

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1670416A1 (de) * 1966-12-30 1971-02-11 Chem Fab Von Heyden Gmbh Muenc Verfahren zur Herstellung von aminosubstituierten Chinazolinonderivaten
JPS6136273A (ja) * 1984-07-26 1986-02-20 Mitsubishi Yuka Yakuhin Kk ２−フエニルアルキル−４（３ｈ）−キナゾリノン誘導体
DE69521500T2 (de) * 1994-03-08 2001-12-13 Otsuka Pharmaceutical Factory, Inc. Phosphorsäurediester-derivate
US5783577A (en) * 1995-09-15 1998-07-21 Trega Biosciences, Inc. Synthesis of quinazolinone libraries and derivatives thereof

Also Published As

Publication number Publication date
WO2001023365A1 (en) 2001-04-05
NO20021502L (no) 2002-03-26
KR20020047186A (ko) 2002-06-21
EP1216235A1 (en) 2002-06-26
NO20021502D0 (no) 2002-03-26
BR0014294A (pt) 2002-05-21
AU7654800A (en) 2001-04-30
CA2385921A1 (en) 2001-04-05

Similar Documents

Publication Publication Date Title
AR025796A1 (es) Quinazolinonas
UY34152A (es) ?oxazolidinonas substituidas y su uso?.
MX9700557A (es) Dihidrobenzofuranos.
ES2122043T3 (es) Nuevos derivados sustituidos del pirazol, procedimientos para su preparacion y su empleo como herbicidas.
TR199801255T2 (xx) Vitronektin resept�r antagonistleri.
DE60230127D1 (de) Inhibitoren von integrin alpha-v-beta-6
ES2193508T3 (es) Ftalizinonas.
AR025797A1 (es) Quinazolinonas
AR010062A1 (es) Nuevos benzamidaldehidos y su utilizacion
DK0960107T3 (da) 6-Thiosubstituerede paclitaxeler
PT1140944E (pt) Derivados de epotilona e sua utilizacao como agentes antitumorais
ES2189235T3 (es) 6-fenilfenantridinas sustituidas.
TR199801253T2 (xx) Vitronektin resept�r� antagonistleri.
ES2184077T3 (es) Nuevas fenantridinas sustituidas en la posicion 6.
TR200200795T2 (tr) 5-HT1B antagonistleri olarak piperazin türevleri
ES2150039T3 (es) Benzonitrilos como 5-ht agonistas y antagonistas.
EE200000033A (et) Uudsed tetrasoolderivaadid
TR199701645A2 (xx) Vitronektin resept�r antagonistleri,bunlar�n imalat� ve kullan�m�
PA8508301A1 (es) Inhibidores de la proteina c del procolageno
PT1086096E (pt) Benzamidas com substituintes etra-hidrofuraniloxi como inibidores da fosfodiesterase 4
ATE391488T1 (de) Haarfärbezusammensetzungen auf basis von diaminopyrazolverbindungen
AR020563A1 (es) Compuestos (poli)tia-alquinoicos y sus derivados, composiciones que los incluyen y su utilizacion
ECSP034813A (es) Arilsulfonamidas como agentes antivirales
AR030537A1 (es) Acidos quinolincarboxilicos y naftiridincarboxilico antibacterianos
PA8466101A1 (es) Agentes terapeuticos